Referrals can be an absolute game-changer in recruitment.When someone in your network recommends a candidate, they often have firsthand insight into the person’s skills, work ethic, values and ambitions. This insider knowledge results in higher quality candidates who are a…
HOME > BUSINESS
BUSINESS
- Results of PIII Trial of Rotarix Published in US Journal Vaccine: GSK
October 10, 2011
- Tsuruha HD to Establish Drugstore Joint Venture in Thailand
October 10, 2011
- Teva, Kowa to Break Up Joint Venture After Just 3 Years
October 10, 2011
- MediciNova Announces Private Sale of Stock to Kissei
October 10, 2011
- Novartis Pharma Donates ¥21 Mil. for Free Medical Exams for Disaster Victims in Soma City
October 10, 2011
- Telavic Approved for Chronic Hepatitis C: MTPC
October 10, 2011
- Takeda Aims at New Drug Development through Open Innovation
October 7, 2011
- Takeda to Offer Information on Actos for Prescribing Doctors
October 7, 2011
- Takeda US Unit Withdraw sNDA for Velcade
October 7, 2011
- Mediceo Aiming for 20% Market Share in Hokkaido within 3 Years: President Watanabe
October 7, 2011
- Eli Lilly Receives Positive Opinion from CHMP for Alimta as Maintenance Therapy for NSCLC
October 7, 2011
- Aiming for 6% Yearly Growth by Rivaroxaban Launching: Bayer AG
October 6, 2011
- Ranbaxy Starts Selling Daiichi Sankyo Drugs in Italy
October 6, 2011
- Eli Lilly Japan Applies for Approval of Fast-Acting Zyprexa Intramuscular Inj.
October 6, 2011
- Nihon Chouzai Introduces Catalog Retailing at All Its Stores
October 6, 2011
- Takeda President Hasegawa Says Innovation Will Take Place in Developing Countries
October 5, 2011
- Ono and Germany’s Merck Enter into License Agreements to Boost Priority Fields
October 5, 2011
- Rating Companies Downgrade Takeda following Acquisition of Nycomed
October 4, 2011
- Mochida’s New 3-Year Business Plan Aims for Sales of ¥100 Bil. in FY2013
October 4, 2011
- Shionogi Announces International Industry-Academic Collaboration Program
October 4, 2011
ページ
Chugai Pharmaceutical’s Phesgo (pertuzumab + trastuzumab + vorhyaluronidase alfa) and Novartis’ Leqvio (inclisiran) will be newly added to the Japanese reimbursement list along with a batch of other medicines on November 22. Three drugs carry peak sales outlooks of over…
The main players in the FY2024 reimbursement policy reform are now all in place, with the roster rounded out by the appointment of former health minister Katsunobu Kato for the Liberal Democratic Party’s (LDP) prominent social security post at the…
Many members of a key reimbursement policy panel on November 10 called on the health ministry to revisit the current listing requirement of at least 25 years for the designation of essential medicines now that annual revisions have been introduced…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…